Drug intelligence / Profile preview

glofitamab + polatuzumab vedotin + zuberitamab

Development stage: Unknown
Lead developer: Roche
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

glofitamab + polatuzumab vedotin + zuberitamab is an investigational combination regimen being evaluated for the treatment of newly diagnosed diffuse large B-cell lymphoma (DLBCL). The regimen combines three distinct therapeutic agents: glofitamab, a bispecific antibody that recruits T cells to CD20-expressing B cells; polatuzumab vedotin, an antibody-drug conjugate (ADC) targeting CD79b that delivers the cytotoxic agent monomethyl auristatin E (MMAE) directly to malignant B cells; and zuberitamab, a monoclonal antibody targeting CD20. This combination is being studied in a Phase II trial (NCT06141330) sponsored by Li Zhiming at Sun Yat-sen University Cancer Center, utilizing a response-adapted approach where patients who do not achieve a complete response may receive additional CHP (cyclophosphamide, doxorubicin, and prednisone) chemotherapy.

Other names: Glofitamab-Pola-ZuberitamabPola-G-Zub

Targets

TUBB (Tubulin (alpha and beta subunits))CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)B-cell antigen receptor complex-associated protein beta chain

Beyond the preview

Go deeper on glofitamab + polatuzumab vedotin + zuberitamab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glofitamab + polatuzumab vedotin + zuberitamab.

Explore the full profile